Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Munson Healthcare is taking steps to make sure Narcan is accessible to everyone.It's partnering with Harm Reduction Michigan ...

Polyrizon is progressing with preparations for its planned 2025 clinical trial. The designated manufacturing facility is equipped to meet the clinical trial material (CTM) requirements, ensuring ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The rink is set at the U.S. Figure Skating Championships in Wichita, Kansas — and the competition is already heating up!

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

New York Governor Kathy Hochul has announced inflation refund checks of up to $500 will be paid to eligible New Yorkers.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.